Personalis, Inc.

Personalis, Inc. develops and sells advanced cancer genomic testing services for precision oncology and research applications. The company serves physicians, pharmaceutical and biopharmaceutical companies, diagnostics firms, universities, non-profits, and government customers from its CLIA-certified, CAP-accredited laboratory in Fremont, California.

−112,0 %

22,7 %

−116,7 %

−17,7 %

6.76

6.76

— Personalis, Inc.
%
Clinical diagnostic testing20% Tumor-informed and other cancer tests used by physicians to guide care and monitor recurrence.
Pharma tests and services45% Testing and analytics for pharmaceutical oncology programs, translational research, and clinical trials.
Enterprise sales15% Tumor profiling and diagnostic inputs sold to other businesses, including Natera-related services.
Population sequencing18% Large-scale sequencing services supporting population genetics and research initiatives.
Other research services2% Genomic tests and analytics sold to universities and non-profit research customers.

Personalis sells to both clinical and research customers, with a large share of revenue tied to a small number of...

  • Pharmaceutical and biopharmaceutical companiesprimary

    They buy testing services and analytics for translational research, biomarker discovery, and clinical trials.

  • Clinical diagnostics / physiciansprimary

    They order NeXT Personal Dx and related cancer tests to detect residual or recurrent disease and support therapy selection.

  • Diagnostics companiessecondary

    They purchase whole exome sequencing and tumor analysis services as inputs to their own diagnostic offerings.

  • Government and population sequencing programssecondary

    They use whole genome sequencing and analytics for large-scale genetic research initiatives.

  • Universities and non-profitsemerging

    They buy genomic testing and analytics for academic and non-commercial research projects.

Personalis derives most of its revenue in the United States, with smaller contributions from Europe, including the U.K...

  • •United States is the main revenue market and operating base
  • •Europe, including the U.K., is a smaller but established market
  • •Asia-Pacific and other regions contribute a limited share of revenue
  • •Fremont, California houses the CLIA and CAP-accredited laboratory
  • •Geographic sales coverage is organized through a small direct sales force

Personalis is focused on expanding adoption of its NeXT Personal testing platform in clinical diagnostics while...

01
Expand clinical diagnostics commercializationshort-term

Clinical adoption can create a broader, more recurring customer base than project-based research work.

02
Build reimbursement and clinical evidencemedium-term

Coverage and published evidence support physician adoption and payer reimbursement.

03
Diversify customer concentrationmedium-term

Reducing dependence on a few large customers lowers volatility from trial timing and renewals.

Personalis faces customer concentration risk because a small number of large accounts can drive a substantial share of...

high

Customer concentration

A few customers account for a large share of revenue, so renewals or project changes can materially affect results.

Scope
Moderna, VA MVP, Natera
Materiality
high
high

Clinical trial and project timing

Pharma and research revenue depends on the start, pace, and completion of external studies.

Scope
Pharma tests and services
Materiality
high
high

Cybersecurity and sensitive data protection

The company processes PHI, genomic data, and financial information, increasing breach and compliance risk.

Scope
Laboratory and third-party systems
Materiality
high
medium

Reimbursement and coverage risk

Clinical diagnostics depend on Medicare and private payer coverage for adoption and volume growth.

Scope
NeXT Personal Dx
Materiality
high
medium

Sustained losses

The company has a history of losses and may need continued capital to support growth and operations.

Scope
Corporate liquidity and operating flexibility
Materiality
high
Revenue recognition
Can shift revenue between quarters and affect comparability
Leases
Affects right-of-use assets, lease liabilities, and expense timing
Common stock warrants
Can materially affect other income/expense and equity
Allowance for credit losses / collectability
Can affect bad debt expense and working capital

Tempus AI, Inc.

TEM · Services-Computer Programming, Data Processing, Etc.

MYRIAD GENETICS INC

MYGN · In Vitro & In Vivo Diagnostic Substances

Caris Life Sciences, Inc.

CAI · Services-Medical Laboratories

NEOGENOMICS INC

NEO · Services-Testing Laboratories

Nautilus Biotechnology, Inc.

NAUT · Laboratory Analytical Instruments

VERACYTE, INC.

VCYT · Services-Medical Laboratories

: 29/04/2026